Mumbai: According to recent research, the global market for Parkinson’s disease (PD) treatments is expected to grow significantly, reaching $7.9 billion by 2033, up from $3.4 billion in 2023. The expansion is primarily driven by advancements in treatment options and the increasing prevalence of the disease due to aging populations.
A study by data and analytics firm GlobalData highlights that the seven major markets—the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan—will witness the most substantial growth, with a projected compound annual growth rate (CAGR) of 8.9% over the forecast period.
Global Parkinson’s Disease Market: Key Drivers of Market Growth
The market’s expansion is attributed to the launch of ten new pipeline drugs, as well as innovative levodopa delivery techniques that improve treatment efficacy. Additionally, the increasing incidence of Parkinson’s disease, largely due to aging populations, is expected to drive demand for effective therapies.
The analysis also forecasts a significant rise in sales across all major PD drug classes, including dopamine agonists, monoamine oxidase B (MOA-B) inhibitors, levodopa treatments, catechol-O-methyltransferase (COMT) inhibitors, and other antiparkinsonian medications. Notably, Parkinson’s dementia medications are expected to experience the fastest growth, with a CAGR of 24.5% during the forecast period.
Global Parkinson’s Disease Market: Addressing an Unmet Need
Experts emphasize the urgent need for better treatments for Parkinson’s dementia, a condition for which rivastigmine is currently the only approved drug among the seven major markets. Lorraine Palmer, a Pharma Analyst at GlobalData, noted that two new medications—Irlab Therapeutics’ pirepemat and Anavex’s blarcamesine—are expected to enter the market by 2033, providing much-needed options for patients.
Global Parkinson’s Disease Market: Future Outlook
By 2033, the introduction of ten late-stage pipeline drugs—including two disease-modifying therapies (DMTs) and several symptomatic treatments—is anticipated to generate an estimated $3.5 billion in sales. These developments are poised to revolutionize Parkinson’s disease treatment by addressing motor complications and cognitive decline more effectively.
The rising prevalence of Parkinson’s disease further underscores the need for advanced treatments. The study predicts that the number of PD patients across the seven major markets will rise from 2.6 million in 2023 to 3.1 million by 2033. Meanwhile, the number of treated cases is expected to increase from 1.9 million to 2.3 million within the same period.
“The market for Parkinson’s disease is quite dynamic, but transformative progress is expected in the next decade. Novel treatments, particularly disease-modifying therapies and drugs targeting new mechanisms, are on the horizon. The late-stage pipeline is well-positioned to meet the growing needs of an expanding patient population,” Palmer added.
With these advancements, the Parkinson’s disease market is poised for significant breakthroughs, bringing new hope to millions of patients worldwide.
